Floatz logo

Adriamycin

Follicular Lymphoma

Merck Sharp & Dohme LLCSmall moleculePhase 4 / ApprovedActive
BB
68/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
70/ 100
Competitive Position
65/ 100

Competitive context

196 Active assets in the Follicular Lymphoma cohort.

Asset / SponsorPhaseRating
Cyclosporin A
Fred Hutchinson Cancer Center
Phase 2/3BBB
Romidepsin
City of Hope Medical Center
Phase 2BBB
Busulfanum
Masonic Cancer Center, University of Minnesota
Phase 2/3BBB
Irinotecan
University of Michigan Rogel Cancer Center
Phase 2BBB
Recombinant Human Hyaluronidase
National Cancer Institute (NCI)
Phase 3BBB

View all 50 →

Same molecule, other indications

Adriamycin is also rated in:

adult acute lymphoblastic leukemiaActive
BBB
Indicative · Phase 4
77 / 100
View asset →
B-cell childhood acute lymphoblastic leukemiaDormant
BBB
Indicative · Phase 3
76 / 100
View asset →
hematopoietic and lymphoid system neoplasmActive
BBB
Indicative · Phase 4
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →